LEGN
Income statement / Annual
Last year (2024), Legend Biotech Corporation's total revenue was $627.24 M,
an increase of 119.97% from the previous year.
In 2024, Legend Biotech Corporation's net income was -$177.03 M.
See Legend Biotech Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$627.24 M |
$285.14 M |
$117.01 M |
$68.83 M |
$75.00 M |
$61.80 M |
$49.13 M |
$23.59 M |
| Cost of Revenue |
$234.58 M
|
$144.21 M
|
$65.36 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$96.00 K
|
| Gross Profit |
$392.66 M
|
$140.93 M
|
$51.64 M
|
$68.83 M
|
$75.00 M
|
$61.80 M
|
$49.13 M
|
$23.69 M
|
| Gross Profit Ratio |
0.63
|
0.49
|
0.44
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$413.54 M
|
$382.22 M
|
$335.65 M
|
$313.35 M
|
$232.16 M
|
$161.94 M
|
$60.64 M
|
$8.20 M
|
| General & Administrative Expenses |
$136.78 M
|
$106.77 M
|
$80.63 M
|
$46.96 M
|
$23.13 M
|
$6.75 M
|
$2.77 M
|
$1.62 M
|
| Selling & Marketing Expenses |
$147.48 M
|
$94.16 M
|
$93.42 M
|
$102.54 M
|
$49.57 M
|
$25.62 M
|
$1.16 M
|
-$217.00 K
|
| Selling, General & Administrative Expenses |
$284.26 M
|
$200.93 M
|
$174.05 M
|
$149.50 M
|
$72.71 M
|
$32.37 M
|
$3.93 M
|
$1.40 M
|
| Other Expenses |
-$1.91 M
|
-$2.73 M
|
-$2.43 M
|
-$1.74 M
|
-$229.87 M
|
$0.00
|
-$2.00 K
|
$0.00
|
| Operating Expenses |
$695.90 M
|
$580.41 M
|
$507.26 M
|
$461.11 M
|
$75.00 M
|
$194.31 M
|
$64.21 M
|
$9.60 M
|
| Cost And Expenses |
$930.48 M
|
$724.63 M
|
$572.63 M
|
$461.11 M
|
$75.00 M
|
$194.31 M
|
$64.21 M
|
$9.81 M
|
| Interest Income |
$61.20 M
|
$54.49 M
|
$8.18 M
|
$971.00 K
|
$2.93 M
|
$4.58 M
|
$6.21 M
|
$1.00 K
|
| Interest Expense |
$21.62 M
|
$21.79 M
|
$10.80 M
|
$900.00 K
|
$4.21 M
|
$223.00 K
|
$82.00 K
|
$0.00
|
| Depreciation & Amortization |
$23.36 M
|
$20.45 M
|
$18.39 M
|
$13.92 M
|
$9.93 M
|
$3.16 M
|
$1.68 M
|
$217.00 K
|
| EBITDA |
-$113.16 M |
-$477.87 M |
-$416.54 M |
-$392.38 M |
-$298.16 M |
-$129.35 M |
$149.00 K |
$14.06 M |
| EBITDA Ratio |
-0.18
|
-1.68
|
-3.56
|
-5.7
|
-3.98
|
-2.09
|
0
|
0.6
|
| Operating Income Ratio |
-0.48
|
-1.54
|
-3.89
|
-5.7
|
0
|
-2.14
|
-0.03
|
0.58
|
| Total Other Income/Expenses Net |
$145.11 M
|
-$80.63 M
|
$9.90 M
|
-$14.91 M
|
-$308.29 M
|
$5.20 M
|
$13.46 M
|
-$40.00 K
|
| Income Before Tax |
-$158.13 M
|
-$520.12 M
|
-$445.72 M
|
-$407.20 M
|
-$308.29 M
|
-$127.32 M
|
-$1.62 M
|
$13.84 M
|
| Income Before Tax Ratio |
-0.25
|
-1.82
|
-3.81
|
-5.92
|
-4.11
|
-2.06
|
-0.03
|
0.59
|
| Income Tax Expense |
$18.89 M
|
-$1.86 M
|
$625.00 K
|
-$3.61 M
|
-$41.91 M
|
-$25.73 M
|
$1.17 M
|
$4.47 M
|
| Net Income |
-$177.03 M
|
-$518.25 M
|
-$446.35 M
|
-$403.58 M
|
-$266.37 M
|
-$101.59 M
|
-$2.78 M
|
$9.37 M
|
| Net Income Ratio |
-0.28
|
-1.82
|
-3.81
|
-5.86
|
-3.55
|
-1.64
|
-0.06
|
0.4
|
| EPS |
-1.94 |
-5.88 |
-5.62 |
-5.48 |
-5.14 |
-2.02 |
-0.0556 |
0.14 |
| EPS Diluted |
-1.94 |
-5.88 |
-5.62 |
-5.48 |
-5.14 |
-2.02 |
-0.0556 |
0.14 |
| Weighted Average Shares Out |
$91.43 M
|
$88.04 M
|
$79.52 M
|
$70.43 M
|
$59.08 M
|
$66.00 M
|
$50.00 M
|
$66.00 M
|
| Weighted Average Shares Out Diluted |
$91.43 M
|
$88.04 M
|
$79.52 M
|
$70.43 M
|
$59.08 M
|
$66.00 M
|
$50.11 M
|
$66.00 M
|
| Link |
|
|
|
|
|
|
|
|
